View ValuationPercheron Therapeutics 将来の成長Future 基準チェック /06Percheron Therapeuticsの収益は年間90.4%で減少すると予測されていますが、年間収益は年間5.5%で増加すると予想されています。EPS は年間91.3%で減少すると予想されています。主要情報-90.4%収益成長率-91.33%EPS成長率Pharmaceuticals 収益成長14.5%収益成長率5.5%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日27 Nov 2025今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 16Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.174875 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.174875 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 434,975,053 Price\Range: AUD 0.005 Security Features: Attached Options Transaction Features: Rights Offeringお知らせ • Aug 28Percheron Therapeutics Limited, Annual General Meeting, Oct 22, 2025Percheron Therapeutics Limited, Annual General Meeting, Oct 22, 2025.お知らせ • Nov 26Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million.Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 135,231,746 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listingお知らせ • Nov 15Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million.Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,160,916 Price\Range: AUD 0.008お知らせ • Oct 23Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 25,000,000 Price\Range: AUD 0.08お知らせ • Oct 18Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 135,231,746 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listingお知らせ • Oct 17Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023, at 14:00 AUS Eastern Standard Time. Location: Minter Ellison, Collins Arch Level 20 447 Collins Street Melbourne VIC 3000 Melbourne Australia Agenda: To receive and consider the Annual Financial Report of the Company for the year ended 30 June 2023 (2023 Annual Report), comprising the Financial Report, the Directors' Report, and the Auditor's Report; to consider Non-Binding Resolution to Adopt the 2023 Remuneration Report; to consider Re-Election of Director Dr. Charmaine Gittleson; to consider Ratification of Prior Issue of Shares to Institutional Investors; to consider Approval for issue of Options to Dr. James Garner; to consider Approval of Employee Share Option Plan; to consider Approval for issue of Options to Dr. Charmaine Gittleson; to consider Approval of change of Company name and modification of Constitution; and to consider Approval of 10% Placement Facility.お知らせ • Jun 29Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UKAntisense Therapeutics Limited announced that it has received both regulatory authority and ethics committee approval to conduct its double-blind, placebo controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy (DMD) in the United Kingdom (UK). Following these approvals, requisite contracts are anticipated to be finalised for initiation of trial sites, expected during third quarter current year 2023.お知らせ • May 08+ 1 more updateAntisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023The Board of Directors of Antisense Therapeutics Limited announced the appointment of Dr James Garner MBBS MBA as Chief Executive Officer (CEO). Dr Garner will assume the roles as of 07 August 2023. This appointment follows the previously announced retirement, on 15 November 2022, of Mr. Mark Diamond from the roles of MD and CEO, with Mark's last working day 12 May 2023. To ensure continuity and leadership, Dr Charmaine Gittleson will assume the role of Executive Chairman, with immediate effect, until James is settled in his CEO and MD duties. James brings broad experience in drug development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector. His previous responsibilities have included leading phase I-IV clinical trials, product registration, reimbursement, and business development. He possesses strong executive leadership and management skills that have seen him achieve outstanding results over a twenty-year career in the Pharmaceutical/Biotechnology industry including roles with Biogen, Progen Pharmaceuticals, Quintiles (an international clinical research organisation) and as Head of the Unit Development Office, AP R&D with Sanofi in Singapore. Most recently James has served as CEO of Kazia Therapeutics Limited.お知らせ • Feb 15Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device AgencyAntisense Therapeutics Limited announced that it has received regulatory authority approval from the Turkish Medicines and Medical Device Agency (TMMDA) to conduct its double-blind, placebo controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy (DMD). As previously advised, the Company had submitted a Clinical Trial Application (CTA) for approval to conduct the Phase IIb trial in UK, Bulgaria and Turkey. This first trial approval by a regulatory authority is an important milestone for the Company in affirming the quality and acceptability of the Phase IIb trial design and critically, in providing the `green light' for trial initiation at expected high patient enrolling sites. The Phase IIb study aims to enrol and randomize 45 non-ambulant boys with DMD from multiple clinical trial sites in Europe and Australia. Following the initial six-month regimen of either placebo, 25 mg or 50 mg ATL1102 once weekly (blinded phase), participants will continue into a further six-month open label treatment period. Trial approvals in Bulgaria, the UK and Australia are expected to come through in a staggered manner depending on the respective regulatory agencies' evaluation process and timelines. The Company will make further announcements as and when material progress updates emerge. As per previous guidance, reporting of the results from the blinded phase of the trial is anticipated in First half of 2024.お知らせ • Feb 03Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMDAntisense Therapeutics Limited reported initial positive muscle functional data from a DMD mdx animal study assessing the use of the combination of antisense (ASO) to CD49d with a dystrophin exon skipping restoration drug. The use of the combination improved the specific maximum force of the extensor digitorum longus (EDL) muscle, a lower leg muscle, and the eccentric muscle force remaining following induced damage to the EDL. This functional data supports the potential use of ATL1102 in combination with dystrophin restoration drugs to improve therapeutic outcomes in patients with DMD. Under the collaborative research agreement with the Murdoch Children's Research Institute's (MCRI), six groups of DMD mdx mice (n=8 per group) were treated for 6 weeks with antisense oligonucleotide to CD49d (mouse equivalent of ATL1102), or control oligonucleotide mismatch or saline treatments, or the morpholino exon skipping dystrophin restoration drug alone and in combination. The muscle physiology of the EDL was assessed for force parameters including specific maximum force and the force drop following 1 to 10 eccentric (lengthening) contraction each involving induced muscle damage by the stretching of the muscle by 10%. The EDL is 1 of 4 muscles in the front of the lower leg whose function is to invert the foot at the ankle. Another of these muscles is the tibialis anterior (TA) on which the ASO to CD49d has previously reported a benefit in reducing eccentric muscle damage in mdx mice. The ASO to CD49d and morpholino exon skipping combination improved the specific maximum force (the maximum force corrected for size/mass and cross-sectional area of the EDL muscle) and both the eccentric muscle force remaining after a single and 10 repeated lengthening contractions with statistically significant effects compared to saline control. This combination after the 10 repeated lengthening contractions, also showed a significant effect (P<0.001) compared to the exon skipping drug used alone and the exon skipping drug used together with the control oligo. In addition, the ASO to CD49d showed a significant effect vs the saline and its control oligo. The morpholino exon skipping drug showed a significant effect compared to the saline control. A provisional patent application titled "Combination Compositions and Methods for Treatment of Muscular Dystrophy" is to be filed to cover the use of the ASO to CD49d and the morpholino exon skipping drug combination to seek protection of the combination of ATL1102 with the dystrophin restoration/exon skipping drugs to 2044, well beyond the patent life of the registered dystrophin restoration drugs. Notably the dystrophin restoration drugs have yet to demonstrate in controlled clinical studies a slowing of the loss of ambulation beyond use of corticosteroids, highlighting the clinical need for a more efficacious therapeutic approach.Further investigations are ongoing in the mdx mouse combination study to determine the possible mechanisms by which the combination approach is providing the observed functional benefits. Muscle RNA and protein samples have been isolated from the mdx mice quadricep muscle for analysis of the dystrophin levels in the muscle to determine if higher levels are seen with the use of the combination than with the dystrophin restoration agent alone. Cellular markers of inflammation and fibrosis including those observed in the ATL1102 DMD Phase II study, will also be assessed to elucidate the potential mechanisms that may be involved. Results from this analysis are anticipated before the end of the first quarter of current year 2023.業績と収益の成長予測OTCPK:PERC.F - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20272-30N/AN/A16/30/20262-9N/AN/A112/31/20252-9-13-10N/A9/30/20252-12-14-13N/A6/30/20252-15-16-16N/A3/31/20252-15-15-15N/A12/31/20242-16-14-14N/A9/30/20242-14-12-12N/A6/30/20243-12-10-10N/A3/31/20243-11-10-10N/A12/31/20233-11-10-10N/A9/30/20232-11-9-9N/A6/30/20232-11-8-8N/A3/31/20232-10-7-7N/A12/31/20222-8-7-7N/A9/30/20222-7-7-7N/A6/30/20222-6-8-8N/A3/31/20221-7-8-8N/A12/31/20211-9-8-8N/A9/30/20211-9-7-7N/A6/30/20211-8-6-6N/A3/31/20211-6-5-5N/A12/31/20201-4-4-4N/A9/30/20201-5-4-4N/A6/30/20201-6-4-4N/A3/31/20201-6-3-3N/A12/31/20191-6-3-3N/A9/30/20191-4N/A-3N/A6/30/20191-3N/A-3N/A3/31/20190-3N/A-3N/A12/31/20180-3N/A-3N/A9/30/20180-3N/A-3N/A6/30/20180-2N/A-2N/A3/31/20180-2N/A-2N/A12/31/20170-2N/A-3N/A9/30/20171-3N/A-3N/A6/30/20171-3N/A-3N/A3/31/20171-2N/A-2N/A12/31/20161-2N/A-2N/A9/30/20162-2N/A-2N/A6/30/20162-3N/A-2N/A3/31/20163-1N/A-1N/A12/31/201541N/A0N/A9/30/201551N/A1N/A6/30/201551N/A1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PERC.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: PERC.F今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: PERC.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: PERC.Fの収益 ( 5.5% ) US市場 ( 11.7% ) よりも低い成長が予測されています。高い収益成長: PERC.Fの収益 ( 5.5% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PERC.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 21:22終値2026/05/22 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Percheron Therapeutics Limited 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Jyoti PrakashEdison Investment Research
お知らせ • Mar 16Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.174875 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.174875 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 434,975,053 Price\Range: AUD 0.005 Security Features: Attached Options Transaction Features: Rights Offering
お知らせ • Aug 28Percheron Therapeutics Limited, Annual General Meeting, Oct 22, 2025Percheron Therapeutics Limited, Annual General Meeting, Oct 22, 2025.
お知らせ • Nov 26Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million.Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 135,231,746 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listing
お知らせ • Nov 15Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million.Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,160,916 Price\Range: AUD 0.008
お知らせ • Oct 23Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 25,000,000 Price\Range: AUD 0.08
お知らせ • Oct 18Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 135,231,746 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 17Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023, at 14:00 AUS Eastern Standard Time. Location: Minter Ellison, Collins Arch Level 20 447 Collins Street Melbourne VIC 3000 Melbourne Australia Agenda: To receive and consider the Annual Financial Report of the Company for the year ended 30 June 2023 (2023 Annual Report), comprising the Financial Report, the Directors' Report, and the Auditor's Report; to consider Non-Binding Resolution to Adopt the 2023 Remuneration Report; to consider Re-Election of Director Dr. Charmaine Gittleson; to consider Ratification of Prior Issue of Shares to Institutional Investors; to consider Approval for issue of Options to Dr. James Garner; to consider Approval of Employee Share Option Plan; to consider Approval for issue of Options to Dr. Charmaine Gittleson; to consider Approval of change of Company name and modification of Constitution; and to consider Approval of 10% Placement Facility.
お知らせ • Jun 29Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UKAntisense Therapeutics Limited announced that it has received both regulatory authority and ethics committee approval to conduct its double-blind, placebo controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy (DMD) in the United Kingdom (UK). Following these approvals, requisite contracts are anticipated to be finalised for initiation of trial sites, expected during third quarter current year 2023.
お知らせ • May 08+ 1 more updateAntisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023The Board of Directors of Antisense Therapeutics Limited announced the appointment of Dr James Garner MBBS MBA as Chief Executive Officer (CEO). Dr Garner will assume the roles as of 07 August 2023. This appointment follows the previously announced retirement, on 15 November 2022, of Mr. Mark Diamond from the roles of MD and CEO, with Mark's last working day 12 May 2023. To ensure continuity and leadership, Dr Charmaine Gittleson will assume the role of Executive Chairman, with immediate effect, until James is settled in his CEO and MD duties. James brings broad experience in drug development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector. His previous responsibilities have included leading phase I-IV clinical trials, product registration, reimbursement, and business development. He possesses strong executive leadership and management skills that have seen him achieve outstanding results over a twenty-year career in the Pharmaceutical/Biotechnology industry including roles with Biogen, Progen Pharmaceuticals, Quintiles (an international clinical research organisation) and as Head of the Unit Development Office, AP R&D with Sanofi in Singapore. Most recently James has served as CEO of Kazia Therapeutics Limited.
お知らせ • Feb 15Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device AgencyAntisense Therapeutics Limited announced that it has received regulatory authority approval from the Turkish Medicines and Medical Device Agency (TMMDA) to conduct its double-blind, placebo controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy (DMD). As previously advised, the Company had submitted a Clinical Trial Application (CTA) for approval to conduct the Phase IIb trial in UK, Bulgaria and Turkey. This first trial approval by a regulatory authority is an important milestone for the Company in affirming the quality and acceptability of the Phase IIb trial design and critically, in providing the `green light' for trial initiation at expected high patient enrolling sites. The Phase IIb study aims to enrol and randomize 45 non-ambulant boys with DMD from multiple clinical trial sites in Europe and Australia. Following the initial six-month regimen of either placebo, 25 mg or 50 mg ATL1102 once weekly (blinded phase), participants will continue into a further six-month open label treatment period. Trial approvals in Bulgaria, the UK and Australia are expected to come through in a staggered manner depending on the respective regulatory agencies' evaluation process and timelines. The Company will make further announcements as and when material progress updates emerge. As per previous guidance, reporting of the results from the blinded phase of the trial is anticipated in First half of 2024.
お知らせ • Feb 03Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMDAntisense Therapeutics Limited reported initial positive muscle functional data from a DMD mdx animal study assessing the use of the combination of antisense (ASO) to CD49d with a dystrophin exon skipping restoration drug. The use of the combination improved the specific maximum force of the extensor digitorum longus (EDL) muscle, a lower leg muscle, and the eccentric muscle force remaining following induced damage to the EDL. This functional data supports the potential use of ATL1102 in combination with dystrophin restoration drugs to improve therapeutic outcomes in patients with DMD. Under the collaborative research agreement with the Murdoch Children's Research Institute's (MCRI), six groups of DMD mdx mice (n=8 per group) were treated for 6 weeks with antisense oligonucleotide to CD49d (mouse equivalent of ATL1102), or control oligonucleotide mismatch or saline treatments, or the morpholino exon skipping dystrophin restoration drug alone and in combination. The muscle physiology of the EDL was assessed for force parameters including specific maximum force and the force drop following 1 to 10 eccentric (lengthening) contraction each involving induced muscle damage by the stretching of the muscle by 10%. The EDL is 1 of 4 muscles in the front of the lower leg whose function is to invert the foot at the ankle. Another of these muscles is the tibialis anterior (TA) on which the ASO to CD49d has previously reported a benefit in reducing eccentric muscle damage in mdx mice. The ASO to CD49d and morpholino exon skipping combination improved the specific maximum force (the maximum force corrected for size/mass and cross-sectional area of the EDL muscle) and both the eccentric muscle force remaining after a single and 10 repeated lengthening contractions with statistically significant effects compared to saline control. This combination after the 10 repeated lengthening contractions, also showed a significant effect (P<0.001) compared to the exon skipping drug used alone and the exon skipping drug used together with the control oligo. In addition, the ASO to CD49d showed a significant effect vs the saline and its control oligo. The morpholino exon skipping drug showed a significant effect compared to the saline control. A provisional patent application titled "Combination Compositions and Methods for Treatment of Muscular Dystrophy" is to be filed to cover the use of the ASO to CD49d and the morpholino exon skipping drug combination to seek protection of the combination of ATL1102 with the dystrophin restoration/exon skipping drugs to 2044, well beyond the patent life of the registered dystrophin restoration drugs. Notably the dystrophin restoration drugs have yet to demonstrate in controlled clinical studies a slowing of the loss of ambulation beyond use of corticosteroids, highlighting the clinical need for a more efficacious therapeutic approach.Further investigations are ongoing in the mdx mouse combination study to determine the possible mechanisms by which the combination approach is providing the observed functional benefits. Muscle RNA and protein samples have been isolated from the mdx mice quadricep muscle for analysis of the dystrophin levels in the muscle to determine if higher levels are seen with the use of the combination than with the dystrophin restoration agent alone. Cellular markers of inflammation and fibrosis including those observed in the ATL1102 DMD Phase II study, will also be assessed to elucidate the potential mechanisms that may be involved. Results from this analysis are anticipated before the end of the first quarter of current year 2023.